AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 80 filers reported holding AVADEL PHARMACEUTICALS PLC in Q1 2021. The put-call ratio across all filers is 0.96 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $0 | -100.0% | 48 | -99.9% | 0.00% | -100.0% |
| Q2 2023 | $813 | -18.7% | 49,335 | +31935.7% | 0.00% | – |
| Q3 2021 | $1,000 | -75.0% | 154 | -78.2% | 0.00% | – |
| Q2 2021 | $4,000 | -96.9% | 708 | -95.0% | 0.00% | – |
| Q1 2021 | $130,000 | +36.8% | 14,303 | +0.6% | 0.00% | – |
| Q4 2020 | $95,000 | +33.8% | 14,215 | +1.4% | 0.00% | – |
| Q3 2020 | $71,000 | -78.4% | 14,015 | -65.5% | 0.00% | – |
| Q2 2020 | $328,000 | +195.5% | 40,615 | +189.1% | 0.00% | – |
| Q1 2020 | $111,000 | – | 14,049 | +200600.0% | 0.00% | – |
| Q1 2019 | $0 | – | 7 | -90.8% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 76 | -65.6% | 0.00% | – |
| Q3 2018 | $1,000 | -88.9% | 221 | -85.5% | 0.00% | – |
| Q2 2018 | $9,000 | -83.0% | 1,521 | -79.4% | 0.00% | – |
| Q1 2018 | $53,000 | -13.1% | 7,371 | -2.6% | 0.00% | – |
| Q4 2017 | $61,000 | +41.9% | 7,570 | +86.2% | 0.00% | – |
| Q3 2017 | $43,000 | +26.5% | 4,065 | +32.6% | 0.00% | – |
| Q2 2017 | $34,000 | – | 3,065 | +4615.4% | 0.00% | – |
| Q1 2017 | $0 | – | 65 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |